Combined treatment of Tourette syndrome with Δ9-THC and dopamine receptor antagonists

Journal of Cannabis Therapeutics

Volumn 2, Issue 3-4, 2002, Pages 145-154

  Müller Vahl, Kirsten R ^a   Schneider, Udo ^a   Emrich, Hinderk M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Amisulpride; Cannabis; Neuroleptics; THC; Tics; Tourette syndrome

Indexed keywords

AMISULPRIDE; BIPERIDEN; CANNABIDIOL; CANNABINOID RECEPTOR AGONIST; CANNABIS; CLOMIPRAMINE; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; DRONABINOL; FLUVOXAMINE; NABILONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; RISPERIDONE; SULPIRIDE; TIAPRIDE;

ADULT; AMENORRHEA; CASE REPORT; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DYSKINESIA; DYSTONIA; FEMALE; GALACTORRHEA; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERKINESIA; IRRITABILITY; PRIORITY JOURNAL; REVIEW; SEDATION; TIC; TREMOR; WEIGHT GAIN;

EID: 0036455078     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v02n03_10     Document Type: Review

References (33)

1. Anderson, L.A., J.J. Anderson, T.N. Chase, and J.R. Walters. 1995. The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res 691(1-2):106-114.
2. Clifford, D.B. 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13(6):669-671.
3. Consroe, P., R. Musty, J. Rein, W. Tillery, and R. Pertwee. 1997. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44-48.
4. Consroe, P., R. Sandyk, and S.R. Snider. 1986. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30(4):277-282.
5. Giuffrida, A., L.H. Parsons, T.M. Kerr, F. Rodriguez de Fonseca, M. Navarro, and D. Piomelli. 1999. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2(4):358-363.
6. Glass, M., M. Dragunow, and R.L. Faull. 2000. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97(3):505-519.
7. Harcherik, D.F., J.F. Leckman, J. Detlor, and D.J. Cohen. 1984. A new instrument for clinical studies of Tourette's syndrome. Am J Acad Child Psychiatry 23(2):153-160.
8. Hemming, M., and P.M. Yellowlees. 1993. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 7(4):389-391.
9. Herkenham, M., A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87(5):1932-1936.
10. Kurlan, R. 2001. New treatments for tics? Neurology 56(5):580-581.
11. Leckman, J.F., K.E. Towbin, S.I. Ort, and D.J. Cohen. 1988. Clinical assessment of tic disorder severity. In Tourette's Syndrome and Tic Disorders, edited by D.J. Cohen, R.D. Bruun, and J.F. Leckman. New York: Wiley.
12. Maneuf, Y.P., A.R. Crossman, and J.M. Brotchie. 1997. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 148(1):265-270.
13. Maneuf, Y.P., J.E. Nash, A.R. Crossman, and J.M. Brotchie. 1996. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308(2):161-164.
14. Meinck, H.M., P.W. Schönle, and B. Conrad. 1989. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236(2):120-122.
15. Moss, D.E., P.Z. Manderscheid, S.P. Montgomery, A.B. Norman, and P.R. Sanberg. 1989. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 44(21):1521-1525.
16. Moss, D.E., S.B. McMaster, and J. Rogers. 1981. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 15(5):779-783.
17. Moss, D.E., S.P. Montgomery, A.A. Salo, and R.W. Steger. 1984. Tetrahydrocannabinol effects on extrapyramidal motor behaviors in an animal model of Parkinson's disease. In The cannabinoids: chemical, pharmacologic, and therapeutic aspects, edited by S. Agurell, W.L. Dewey, and R.E. Willette. New York: Academic Press.
18. Müller-Vahl, K.R., H. Kolbe, U. Schneider, and H.M. Emrich. 1998. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiat Scand 98(6):502-506.
19. 9-Tetrahydrocannabinol (THC). Pharmacopsychiatry, in press.
20. Müller-Vahl, K.R., U. Schneider, H. Kolbe, and H.M. Emrich. 1999. Treatment of Tourette-Syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156(3): 495.
21. Müller-Vahl K.R., U. Schneider, K. Theloe, H. Prevedel, H. Kolbe, and H.M. Emrich. 2001. Cannabinoids in the Treatment of Tourette-Syndrome. International Association for Cannabis as Medicine, 2001 Congress on Cannabis and Cannabinoids, 26-27 October, 2001, Berlin, Abstracts.
22. Navarro, M., J.J. Fernandez-Ruiz, R. De Miguel, M.L. Hernandez, M. Cebeira, and J.A. Ramos. 1993. Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 45(2):291-298.
23. Pertwee, R.G., and A.P. Wickens AP. 1991. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30(3):237-244.
24. Rodriguez de Fonseca, F., J.L. Martin Calderon, R. Mechoulam, and M. Navarro. 1994. Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxydelta 8-tetrahydrocannabinol-dimethyl-heptyl-induced catalepsy in male rats. Neuroreport 5(7):761-765.
25. Sandyk, R., and G. Awerbuch. 1988. Marijuana and Tourette's syndrome. J Clin Psychopharmacol 8(6):444-445.
26. Sandyk, R., S.R. Snider, P. Consroe, and S.M. Elias. 1986. Cannabidiol in dystonic movement disorders. Psychitry Res 18(3):291.
27. Shapiro, A.K., E.S. Shapiro, J.G. Young, and T.E. Feinberg. 1988. Signs, symptoms, and clinical course. In Gilles de la Tourette Syndrome, 2nd ed., edited by A.K. Shapiro, E.S. Shapiro, J.G. Young, and T.E. Feinberg. New York: Raven Press.
28. Sieradzan, K.A., S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie. 2001. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57(11):2108-2111.
29. Singer, H.S. 1997. Neurobiology of Tourette syndrome. Neurol Clin 15(2):357-379.
30. Snider, S.R., and P. Consroe. 1984. Treatment of Meige's syndrome with cannabidiol. Neurology 34(Suppl): 147.
31. Souilhac, J., M. Poncelet, M. Rinaldi-Carmona, G. Le Fur, and P. Soubrie. 1995. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 51(1):3-7.
32. Trillet, M., T. Moreau, J. Dalery, R. de Villard, and G. Aimard. 1990. Treatment of Gilles de la Tourette's disease with amisulpride. Presse Med 19(4):175.
33. Wickens, A.P., and R.G. Pertwee. 1995. Effect of delta 9-tetrahydrocannabinol on circling in rats induced by intranigral muscimol administration. Eur J Pharmacol 282(1-3):251-254.